These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31417315)

  • 1. Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study.
    Kitagawa Y; Osumi H; Shinozaki E; Ota Y; Nakayama I; Suzuki T; Wakatsuki T; Ichimura T; Ogura M; Ooki A; Takahari D; Suenaga M; Chin K; Yamaguchi K
    Cancer Manag Res; 2019; 11():5757-5764. PubMed ID: 31417315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma.
    Ando T; Hosokawa A; Yoshita H; Ueda A; Kajiura S; Mihara H; Nanjo S; Fujinami H; Nishikawa J; Ogawa K; Nakajima T; Imura J; Sugiyama T
    Gastroenterol Res Pract; 2015; 2015():425876. PubMed ID: 26199623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy.
    Nio K; Arita S; Isobe T; Kusaba H; Kohashi K; Kajitani T; Tamura S; Hirano G; Mitsugi K; Makiyama A; Esaki T; Ariyama H; Oda Y; Akashi K; Baba E
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):829-35. PubMed ID: 25702050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract.
    Araki T; Takashima A; Hamaguchi T; Honma Y; Iwasa S; Okita N; Kato K; Yamada Y; Hashimoto H; Taniguchi H; Kushima R; Nakao K; Boku N; Shimada Y
    Anticancer Drugs; 2016 Sep; 27(8):794-9. PubMed ID: 27341105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amrubicin Monotherapy for Patients with Platinum-Pretreated Non-Gastrointestinal Non-Pancreatic Extrapulmonary Neuroendocrine Carcinoma.
    Ebata T; Shimoi T; Ishiwata T; Iwasawa S; Bun S; Yunokawa M; Yonemori K; Takiguchi Y; Tamura K
    Oncology; 2017; 93(3):177-182. PubMed ID: 28521313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of Amrubicin Monotherapy for Patients with Extrapulmonary Neuroendocrine Carcinomas Refractory to Platinum-Based Chemotherapy].
    Funasaka C; Kanemasa Y; Kageyama A; Shimoyama T; Omuro Y
    Gan To Kagaku Ryoho; 2020 Aug; 47(8):1205-1208. PubMed ID: 32829355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases.
    Asayama M; Fuse N; Yoshino T; Yano T; Tahara M; Doi T; Fujii S; Ohtsu A
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1325-30. PubMed ID: 21461890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage Chemotherapy by FOLFIRI Regimen for Poorly Differentiated Gastrointestinal Neuroendocrine Carcinoma.
    Sugiyama K; Shiraishi K; Sato M; Nishibori R; Nozawa K; Kitagawa C
    J Gastrointest Cancer; 2021 Sep; 52(3):947-951. PubMed ID: 32918273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901).
    Murakami H; Yamamoto N; Shibata T; Takeda K; Ichinose Y; Ohe Y; Yamamoto N; Takeda Y; Kudoh S; Atagi S; Satouchi M; Kiura K; Nogami N; Endo M; Watanabe H; Tamura T
    Lung Cancer; 2014 Apr; 84(1):67-72. PubMed ID: 24530204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
    Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer.
    Igawa S; Ono T; Kasajima M; Manabe H; Fukui T; Mitsufuji H; Yokoba M; Kubota M; Katagiri M; Sasaki J; Naoki K
    Cancer Manag Res; 2020; 12():4911-4921. PubMed ID: 32606979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
    Ettinger DS; Jotte R; Lorigan P; Gupta V; Garbo L; Alemany C; Conkling P; Spigel DR; Dudek AZ; Shah C; Salgia R; McNally R; Renschler MF; Oliver JW
    J Clin Oncol; 2010 May; 28(15):2598-603. PubMed ID: 20385980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients.
    Kushiro K; Watanabe S; Goto Y; Fujisaki T; Yanagimura N; Ohtsubo A; Shoji S; Nozaki K; Tanaka T; Saida Y; Sato Y; Ota T; Koshio J; Hayashi Y; Miyabayashi T; Matsumoto N; Ichikawa K; Koyama K; Kikuchi T
    Transl Lung Cancer Res; 2022 Sep; 11(9):1858-1865. PubMed ID: 36248339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status.
    Igawa S; Shirasawa M; Ozawa T; Nishinarita N; Okuma Y; Ono T; Sugimoto A; Kurahayashi S; Sugita K; Sone H; Fukui T; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Thorac Cancer; 2018 Aug; 9(8):967-973. PubMed ID: 29870153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: A retrospective study.
    Sone H; Igawa S; Kasajima M; Ishihara M; Hiyoshi Y; Hosotani S; Ohe S; Ito H; Kaizuka N; Manaka H; Fukui T; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Thorac Cancer; 2018 Oct; 9(10):1279-1284. PubMed ID: 30126051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective analysis of Japanese patients with relapse or refractory small-cell lung cancer treated with amrubicin hydrochloride.
    Kim YH; Mio T; Masago K; Irisa K; Sakamori Y; Mishima M
    Oncol Lett; 2010 May; 1(3):569-572. PubMed ID: 22966345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma.
    Hirai F; Seto T; Yamanaka T; Toyozawa R; Inamasu E; Kojo M; Toyokawa G; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
    Jpn J Clin Oncol; 2013 Oct; 43(10):1018-22. PubMed ID: 23917962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amrubicin monotherapy may be an effective second-line treatment for patients with large-cell neuroendocrine carcinoma or high-grade non-small-cell neuroendocrine carcinoma.
    Kasahara N; Wakuda K; Omori S; Nakashima K; Ono A; Taira T; Kenmotsu H; Naito T; Murakami H; Mori K; Watanabe R; Endo M; Nakajima T; Yamada M; Takahashi T
    Mol Clin Oncol; 2017 May; 6(5):718-722. PubMed ID: 28529747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic granulocyte-colony stimulating factor in patients with lung neuroendocrine carcinoma receiving platinum agents plus etoposide.
    Watanabe H; Karayama M; Yasui H; Inoue Y; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suda T
    Cancer Treat Res Commun; 2021; 29():100493. PubMed ID: 34844181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.
    Mitsuoka S; Kudoh S; Kimura T; Yoshimura N; Tanaka H; Suzumura T; Umekawa K; Nagata M; Ueda T; Hirata K
    Osaka City Med J; 2011 Dec; 57(2):59-66. PubMed ID: 22443079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.